These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 18818117)

  • 1. Mechanisms of proteasome inhibitor action and resistance in cancer.
    McConkey DJ; Zhu K
    Drug Resist Updat; 2008; 11(4-5):164-79. PubMed ID: 18818117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of proteasome in malignant diseases.
    Moran E; Nencioni A
    J BUON; 2007 Sep; 12 Suppl 1():S95-9. PubMed ID: 17935285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of proteasome inhibitors in oncology and autoimmune diseases.
    Bennett MK; Kirk CJ
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):616-25. PubMed ID: 18729013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel role for a familiar protein in apoptosis induced by proteasome inhibition.
    McConkey DJ
    Cancer Cell; 2008 Jul; 14(1):1-2. PubMed ID: 18598936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The development and pharmacology of proteasome inhibitors for the management and treatment of cancer.
    Ruggeri B; Miknyoczki S; Dorsey B; Hui AM
    Adv Pharmacol; 2009; 57():91-135. PubMed ID: 20230760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteasome inhibitors in cancer therapy: lessons from the first decade.
    Orlowski RZ; Kuhn DJ
    Clin Cancer Res; 2008 Mar; 14(6):1649-57. PubMed ID: 18347166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.
    von Metzler I; Heider U; Mieth M; Lamottke B; Kaiser M; Jakob C; Sezer O
    Exp Cell Res; 2009 Aug; 315(14):2471-8. PubMed ID: 19410573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
    Landis-Piwowar KR
    Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
    Orlowski RZ
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteasome inhibition by bortezomib decreases proliferation and increases apoptosis in ovarian granulosa cell tumors.
    Chu S; Alexiadis M; Fuller PJ
    Reprod Sci; 2009 Apr; 16(4):397-407. PubMed ID: 19087975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
    Cvek B; Dvorak Z
    Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The putative roles of the ubiquitin/proteasome pathway in resistance to anticancer therapy.
    Smith L; Lind MJ; Drew PJ; Cawkwell L
    Eur J Cancer; 2007 Nov; 43(16):2330-8. PubMed ID: 17888650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The peptide-semicarbazone S-2209, a representative of a new class of proteasome inhibitors, induces apoptosis and cell growth arrest in multiple myeloma cells.
    Baumann P; Müller K; Mandl-Weber S; Leban J; Doblhofer R; Ammendola A; Baumgartner R; Oduncu F; Schmidmaier R
    Br J Haematol; 2009 Mar; 144(6):875-86. PubMed ID: 19170678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome inhibitors in multiple myeloma.
    Anderson KC
    Semin Oncol; 2009 Apr; 36(2 Suppl 1):S20-6. PubMed ID: 19393832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor chemotherapy utilizing peptide-based approaches--apoptotic pathways, kinases, and proteasome as targets.
    Mendoza FJ; Espino PS; Cann KL; Bristow N; McCrea K; Los M
    Arch Immunol Ther Exp (Warsz); 2005; 53(1):47-60. PubMed ID: 15761376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteasome inhibitors in pediatric cancer treatment.
    Bachmann AS
    Hawaii Med J; 2008 Sep; 67(9):247-9. PubMed ID: 18853901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade.
    Yerlikaya A; Erin N
    Int J Mol Med; 2008 Dec; 22(6):817-23. PubMed ID: 19020781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAG3 gene silencing sensitizes leukemic cells to Bortezomib-induced apoptosis.
    Liu P; Xu B; Li J; Lu H
    FEBS Lett; 2009 Jan; 583(2):401-6. PubMed ID: 19111544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory NF-kappaB activation promotes hepatic apolipoprotein B100 secretion: evidence for a link between hepatic inflammation and lipoprotein production.
    Tsai J; Zhang R; Qiu W; Su Q; Naples M; Adeli K
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1287-98. PubMed ID: 19342510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-XL protein is markedly decreased in UVB-irradiated basal cell carcinoma cell lines through proteasome-mediated degradation.
    Park K; Lee JH
    Oncol Rep; 2009 Mar; 21(3):689-92. PubMed ID: 19212627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.